Abstract session 03/06/2020
Persistence of biologic treatment in psoriatic arthritis: A population-based study in Sweden
Mr. Kirk

Abstract session 05/06/2020
The IMPACT of a referral strategy for axial spondyloarthritis: 12 months follow-up of patient reported outcomes
Ms. Maha Jamal

Abstract session 04/06/2020
Biologics may prevent cardiovascular events in rheumatoid arthritis by inhibiting coronary plaque formation and stabilizing high-risk lesions
Mr. George

Abstract session 05/06/2020
Use of hydroxychloroquine and risk of heart failure in patients with Rheumatoid Arthritis
Mr. Ahmed

Abstract session 03/06/2020
Prediction of remission for each biologics based on patient’s clinical information before starting biologics using explainable artificial intelligence
Dr. Laura

Abstract session 03/06/2020
Exponential therapy, improving osteoclastic and upregulated frailty in patients with inflammatory arthropathy
Dr. Ellis

Abstract session 05/06/2020
A CROSS-SECTIONAL, MATCHED-PAIR ANALYSIS OF ACPA POSITIVE AND ACPA NEGATIVE RHEUMATOID ARTHRITIS PATIENTS COMPARING THE PREVALENCE OF OSTEOPOROSIS, FRAGILITY FRACTURES AND UNDERLYING RISK FACTORS
Dr. Edgar

Abstract session 05/06/2020
Effecacy and Safety of NON-OPIOID ANTI-INFLAMMATORY DRUGS (NSAIDS) and Methyl-PREDNISOLONE in POSTNATAL FEMALE NEWBORN
Dr. Berna

Abstract session 04/06/2020
Differential interference of co-morbidities on site of fragility fractures
Dr. Mrinalini

Abstract session 03/06/2020
Cumulative antibiotic use and the risk of developing Ankylosing Spondylitis: a population-based case control study.
Ms. Ana

Abstract session 04/06/2020
Whole blood RNA expression in clinically suspected arthralgia patients shows a potential added value in prediction of inflammatory arthritis
PhD Ellis

Abstract session 03/06/2020
EXAMINATION OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS – PREVALENCE, TIME TO ONSET, AND CLINICAL CHARACTERISTICS
Ms. Yuexi

Abstract session 06/06/2020
DOES THE RISK OF VENOUS THROMBOEMBOLISM VARY WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS?
MD Viktor

Abstract session 03/06/2020
Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease
Dr. Jerome

Abstract session 03/06/2020
The Analysis of the Involvement of Transforming-growth Interacting Factor Polymorphisms in the Bone Metabolism of Rheumatoid Arthritis
Ms. Huiling

Abstract session 04/06/2020
The Impact of Drug-Induced Venous Thromboembolism on Mortality, Hospitalization, and Quality of Life among Patients with Rheumatoid Arthritis in the USA
Dr. Jie

Abstract session 04/06/2020
Cardiovascular disease and malignancies in RA
Dr. George

Abstract session 04/06/2020
Immune Checkpoint Inhibitors therapies are safe and effective for patients with cancer and preexisting autoimmune disease?
Dr. Wenhui

Abstract session 05/06/2020
The IMPACT of a referral strategy for axial spondyloarthritis: 12 months follow-up of patient reported outcomes
Ms. Maha Jamal

Abstract session 05/06/2020
The IMPACT of a referral strategy for axial spondyloarthritis: 12 months follow-up of patient reported outcomes
Ms. Maha Jamal

Abstract session 05/06/2020
Persistence of biologic treatment in psoriatic arthritis: A population-based study in Sweden
Mr. Kirk

Abstract session 03/06/2020
Use of hydroxychloroquine and risk of heart failure in patients with Rheumatoid Arthritis
Mr. Ahmed

Abstract session 05/06/2020
The IMPACT of a referral strategy for axial spondyloarthritis: 12 months follow-up of patient reported outcomes
Ms. Maha Jamal

Abstract session 05/06/2020
The IMPACT of a referral strategy for axial spondyloarthritis: 12 months follow-up of patient reported outcomes
Ms. Maha Jamal

Abstract session 03/06/2020
Persistence of biologic treatment in psoriatic arthritis: A population-based study in Sweden
Mr. Kirk

Abstract session 05/06/2020
The IMPACT of a referral strategy for axial spondyloarthritis: 12 months follow-up of patient reported outcomes
Ms. Maha Jamal

Abstract session 05/06/2020
The IMPACT of a referral strategy for axial spondyloarthritis: 12 months follow-up of patient reported outcomes
Ms. Maha Jamal

Abstract session 03/06/2020
Persistence of biologic treatment in psoriatic arthritis: A population-based study in Sweden
Mr. Kirk

Abstract session 03/06/2020
Persistence of biologic treatment in psoriatic arthritis: A population-based study in Sweden
Mr. Kirk
16 - New avenues in treating systemic lupus, Sjögren's and APS (not guided) 06/06/2020
Preclinical and clinical characterization of cenerimod, a potent, selective, and orally active sphingosine-1-phosphate receptor 1 modulator in SLE
Dr. Mark

16 - New avenues in treating systemic lupus, Sjögren's and APS (not guided) 06/06/2020
Hydroxychloroquine prescription patterns in Europe - the European survey for lupus patients (ESLP)
Mr. Zgjim

1. Genomics, genetic basis of disease and functional genomics 04/06/2020
Comparative transcriptome analyses across tissues and species identify targetable genes for human Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN)
Ms. Eleni

1. Genomics, genetic basis of disease and functional genomics 04/06/2020
Type I interferon signature predicts progression to inflammatory arthritis in ACPA+ at-risk individuals without clinical synovitis
Dr. Leticia

1. Genomics, genetic basis of disease and functional genomics 04/06/2020
Identification of muscle associated key genes to support axial spondyloarthritis diagnosis by transcriptomic approach, the MyoSpA study
Ms. Atlas

1. Genomics, genetic basis of disease and functional genomics 04/06/2020
An explanation for how viral infection may trigger spondyloarthropathy based on TLR9 driven TNF responses from entheseal derived plasmacytoid dendritic cells
Dr. Qiao

1. Genomics, genetic basis of disease and functional genomics 04/06/2020
Epigenomic analysis of RA patients shows distinct biological processes associated with anti-TNF response
PhD Antonio

1. Genomics, genetic basis of disease and functional genomics 04/06/2020
Detailed profile of co-occurrence of selecting Polyadenylated and Alternative Stem-Transcriptome Science and their association with regulation of Sclerosis
Dr. Dipgan

2. Adaptive immunity (T cells and B cells) in rheumatic diseases 04/06/2020
Low-dose interleukin-2 selectively expands and activates regulatory T cells across 13 autoimmune diseases.
MD, PhD Michelle

2. Adaptive immunity (T cells and B cells) in rheumatic diseases 04/06/2020
Contribution of defective non-apoptotic Fas signaling to immune dysregulation in autoimmune lymphoproliferative syndrome (ALPS)
Mr. Julian

3. Innate immunity in rheumatic diseases 04/06/2020
R835, a novel IRAK1/4 dual inhibitor in clinical development, blocks Toll-like receptor 4 (TLR4) signaling in human and mouse
Dr. Vanessa

4. OA, aetiology, pathology and animal models 04/06/2020
Functional MR Imaging of Human Meniscus is Associated with Histological Degeneration
PD Dr. Philipp

5. Bone diseases, including osteoporosis and osteoimmunology: aetiology, pathology and animal models 04/06/2020
Effect of carbamylation of low-density lipoproteins on bone cells homeostasis
MD Bruno

6. Rheumatoid arthritis - aetiology, pathogenesis and animal models 04/06/2020
CXCL7 promotes osteoclastogenesis in rheumatoid arthritis
Ms. Xinyu

6. Rheumatoid arthritis - aetiology, pathogenesis and animal models 04/06/2020
Resolvin D5 modulates Th17/Treg cell differentiation and suppresses osteoclastogenesis
Dr. Hirotaka

6. Rheumatoid arthritis - aetiology, pathogenesis and animal models 04/06/2020
Expression profile analysis of long noncoding RNAs induced by IL-1ß in rheumatoid arthritis fibroblast-like synoviocytes
Prof. Ji-Min

6. Rheumatoid arthritis - aetiology, pathogenesis and animal models 04/06/2020
Histopathological Changes of Synovial Tissue in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Dr. Yoshinori

6. Rheumatoid arthritis - aetiology, pathogenesis and animal models 04/06/2020
Sonic hedgehog promotes synovial hyperplasia and bone damage through p38 MAPK signaling in experimental arthritis
Prof. Jianlin
04/06/2020 Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to tumor necrosis factor inhibitors

04/06/2020 Risk of malignancy with non-TNF biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies

04/06/2020 Comparison of the synovial response to mechanical stress among patients with rheumatoid arthritis in clinical remission on Methotrexate or Anti-TNF MD, PhD Carlos

04/06/2020 Real-world experience of switching from substitutive to biologic rheumathoid arthritis

04/06/2020 TREATMENT OF A COHORT OF PATIENTS WITH INTERSTITIAL LUNG DISEASE AND RHEUMATOID ARTHRITIS

04/06/2020 SIGNIFICANT IMPROVEMENT OF NT‐PROBNP LEVELS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOCILIZUMAB AND TOFACITINIB

04/06/2020 Response to Abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis

04/06/2020 Abatacept and low gamma-globulin levels: no association with infectious risk or RA disease activity control

04/06/2020 THE RELATIONSHIP BETWEEN THE ADMINISTRATION OF IL‐6 INHIBITORS AND INSULIN RESISTANCE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

04/06/2020 STEROID‐SPARING EFFECT OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS PATIENTS FOLLOWED UP IN A REAL LIFE SETTING

04/06/2020 GENDER DOES NOT INFLUENCE CLINICAL RESPONSE TO JAK INHIBITORS IN RHEUMATOID ARTHRITIS: AN ITALIAN MULTICENTRE ANALYSIS

04/06/2020 RELATIONSHIP BETWEEN MELATONIN SERUM LEVELS AND THE EFFICACY OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR PAROXETINE IN PATIENTS WITH RHEUMATOID ARTHRITIS
15. Rheumatoid arthritis - non-biologic treatment and small molecules

(04/06/2020) A Phase 1 study in healthy volunteers exploring the safety, pharmacokinetics and pharmacodynamics of AT-450: a novel oral MK2 inhibitor

Dr. David

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 A Phase 1 study in healthy volunteers exploring the safety, pharmacokinetics and pharmacodynamics of AT-450: a novel oral MK2 inhibitor

Dr. David

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 EFFECT OF JAK INHIBITORS ON PAIN AND QUALITY OF LIFE IN RHEUMATOID ARTHRITIS PATIENTS

Dr. Francesca Romana

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 First-in-human Study of Safety, Pharmacokinetics and Pharmacodynamics of IRAK1/4 Inhibitor R835 in Healthy Subjects

Dr. Lucy

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 Long-term Effectiveness of Tofacitinib in Conventional DMARDS Non-Responders with Rheumatoid Arthritis. Results of Russian National Register

Prof. Dr. Inna

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 Tofacitinib in patients with rheumatoid arthritis and indicative of depression and/or anxiety: a post-hoc analysis of Phase 3 and Phase 3b/4 clinical trials

Dr. Gustavo

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH 1 52-Week Results

Dr. Bernard

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 Long-term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 weeks from the SELECT-COMBO Study

Prof. Dr. Peter C.

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis

Prof. Dr. Josef S.

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis

Dr. Mark C.

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 The efficacy and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse of rheumatoid arthritis

Dr. Juan

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 A Subgroup Analysis of Low Disease Activity and Remission from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs

Prof. Dr. Jacques Eric

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 Methotrexate therapy is not associated with an increased risk of liver fibrosis assessed by the fibrosis-4 index

Prof. Jerome

(04/06/2020) Rheumatoid arthritis - non-biologic treatment and small molecules

04/06/2020 Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib

Dr. Kevin

16. SLE, Sjögren's and APS - treatment

(04/06/2020) Abnormality Tfh subsets indicate disease activity while sirolimus therapy restores the PD-1+ICOS+Tfh/activated Tfr balance in primary Sjogren's Syndrome patients

MD Yanlin

(04/06/2020) SLE, Sjögren's and APS - treatment

04/06/2020 High-dose steroids are important contributors to the infection burden of patients with lupus nephritis

Dr. Bogdan

(04/06/2020) SLE, Sjögren's and APS - treatment

04/06/2020 Antimalarial drugs associated Retinopathy in Systemic Lupus Erythematosus

MD Ximena Elizabeth

(04/06/2020) SLE, Sjögren's and APS - treatment

04/06/2020 Lack of efficacy of Rivaroxaban in the Treatment of antiphospholipid syndrome and clinical significance of antiphospholipid antibodies

Dr. Syuzanna

(04/06/2020) SLE, Sjögren's and APS - treatment

04/06/2020 Predictors of poor renal outcome in patients with proliferative lupus nephritis: a 36-months cohort study

Dr. Mariana

(04/06/2020) SLE, Sjögren's and APS - treatment

04/06/2020 Plasma proteomics identifies a protein signature associated with response to rituximab in patients with SLE

Dr. John
16. SLE, Sjögren's and APS - treatment

06/09/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Ewa

06/06/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Miloslav

06/05/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Heike

16. SLE, Sjögren's and APS - treatment

05/31/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Thuy Linh

05/28/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Yasmin

05/25/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Jurgita

05/22/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Fei

05/19/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Saeid

05/16/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Sebastian

05/13/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. KATRINA

05/10/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Carmen Magda

05/07/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Ying

05/04/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Maria

05/01/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Rabanto

16. SLE, Sjögren's and APS - treatment

04/28/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Jinhong

04/25/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Kiebi

04/22/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Shu

04/19/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Nguyen

04/16/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Ying

04/13/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Sarah

04/10/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Xiubin

04/07/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Rose

04/04/2020 Sample Sizes and Recruitment Rates Are Decreasing While Placebo Response Rates Are Increasing in Clinical Trials for Systemic Lupus Erythematosus - a Manifesto for New Strategies
Dr. Richard
Scleroderma, myositis and related syndromes

19. Scleroderma, myositis and related syndromes

04/06/2020 DIGITAL ARTERY VOLUME INDEX (DAVI©) PREDICTS THE ONSET OF FUTURE DIGITAL ULcers IN PATIENTS WITH SYSTEMIC SCLEROSIS
Dr. Francesco

04/06/2020 In myositis patients, Sjögren’s syndrome is associated with inclusion body myositis and with anti-cN1A antibodies independently of the myositis subtype
MD Dan

04/06/2020 Negative Changes of Body Composition in Myositis Patients and their Association with Disease Specific Characteristics, Physical Activity and Nutritional Status.
MD Sabine

04/06/2020 Combination of computed tomography scan and serum myositis specific/associated autoantibodies helps early identify and treat patients with IPAF and CTD-ILD
Dr. Chun-Chi

04/06/2020 IMPACT AND ADHERENCE TO THE MEDITERRANEAN DIET IN SYSTEMIC SCLEROSIS ITALIAN PATIENTS: CORRELATION WITH GASTROINTESTINAL SYMPTOMS, MOOD DISTURBANCES AND QUALITY OF LIFE
Dr. Giacomo

04/06/2020 Are myositis antibodies specific for idiopathic inflammatory myopathy diagnosis? Clinical correlation of a cohort of patients positive for myositis antibodies
MD Jesús

04/06/2020 Combination of biomarkers of autoinflammatory disease in patients with systemic sclerosis shows diffuse fibrosis
Ms. Fabrizio

04/06/2020 Combination of angiography and DEXA measurement of pulmonary involvement in myositis patients shows diffuse fibrosis
MD Sabrina

04/06/2020 Prevalence and risk factors for left ventricular diastolic dysfunction in Systemic Sclerosis: Results from the RESCL registry
MD, PhD Andrés

04/06/2020 Autoimmune treatment in patients with systemic sclerosis
Dr. Mario

04/06/2020 Stellate blockade combined to iloprost as supportive treatment option improves pain and ischaemic symptoms in patients with systemic sclerosis
Ms. Franziska

04/06/2020 Prognostic factors for the treatment of idiopathic inflammatory myopathies: implications for clinical practice
MD Liudmila

04/06/2020 Serum Metabolites as Biomarkers in Systemic Sclerosis-Associated Interstitial Lung Disease
Dr. med. Chantal

04/06/2020 New immunomodulatory combination therapies in patients with systemic sclerosis: a retrospective cross-sectional study
Prof. Xiaofeng

04/06/2020 The effect of plasma exchange therapy for anti-MDA5 antibody-positive refractory interstitial lung disease
MD Yoshiyuki

04/06/2020 Generalized indicator of Raynaud’s phenomenon expression for evaluation of clinical efficacy of prostanoid therapy
Dr. Gregory

04/06/2020 The effectiveness of plasma exchange therapy for anti-MDA5 antibody-positive refractory interstitial lung disease
Dr. Richard

04/06/2020 Prognostic factors for chronic fine-vessels in patients with idiopathic pulmonary fibrosis
Dr. Philip

04/06/2020 Prognostic factors for idiopathic pulmonary fibrosis in patients with systemic sclerosis
Dr. Philip

04/06/2020 Generalized indicator of Raynaud’s phenomenon expression for evaluation of clinical efficacy of prostanoid therapy
Dr. Philip

04/06/2020 Prognostic factors for idiopathic pulmonary fibrosis in patients with systemic sclerosis
Dr. Philip
26. **Spondyloarthritis – treatment**

26. **Spondyloarthritis – treatment**

**20. Spondyloarthritis – treatment 04/06/2020**

Effectiveness of switching between TNF inhibitors in patients with spondyloarthritis: is the reason to switch relevant? Dr. Santiago

**20. Spondyloarthritis – treatment 04/06/2020**

Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant? Dr. Santiago

**20. Spondyloarthritis – treatment 04/06/2020**

HOW DO TNF‐ALPHA‐INHIBITORS IN MEDICAL HISTORY AFFECT PATIENT REPORTED OUTCOMES AND RETENTION IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH SECUKINUMAB IN REAL WORLD? – GERMAN AQUILA STUDY Dr. Daniel

**20. Spondyloarthritis – treatment 04/06/2020**

IMPACT OF HLA‐B27 STATUS ON CLINICAL OUTCOMES AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB Dr. Atul

**20. Spondyloarthritis – treatment 04/06/2020**

Predictors of maintenance of secukinumab treatment in a multicenter cohort of 610 patients Dr. Marios

**20. Spondyloarthritis – treatment 04/06/2020**

The influence of obesity on treatment response to biologic agents in ankylosing spondylitis MD, PhD Jae‐Hoon

**20. Spondyloarthritis – treatment 04/06/2020**

Management of cardiovascular comorbidity in Psoriatic Arthritis in the routine clinical practice: A comparative study of methotrexate or apremilast as monotherapy and combined Dr. Nuria

**20. Spondyloarthritis – treatment 04/06/2020**

Secukinumab is frequently preferred in multi anti‐TNF resistance spondyloarthritis patients: HUR‐BIO real life results MD Berkan

**20. Spondyloarthritis – treatment 04/06/2020**

Obesity is a strong predictor of worse clinical outcomes and treatment responses to biologics in patients with ankylosing spondylitis Dr. Feng

**20. Spondyloarthritis – treatment 04/06/2020**

EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN NAïVE OR TNF‐INHIBITORS FAILURE PSAORTIC ARTHRITIS PATIENTS IN REAL LIFE: A 24‐MONTHS PROSPECTIVE MULTICENTER STUDY MD Mariagrazia

**20. Spondyloarthritis – treatment 04/06/2020**

FACTORS ASSOCIATED WITH PERSISTENCE OF GOLIMUMAB TREATMENT IN THE BIOBADASER REGISTRY, UP TO 7 YEARS OF FOLLOW‐UP MD, PhD Manuel

**20. Spondyloarthritis – treatment 04/06/2020**

Conventional disease‐modifying antirheumatic drugs therapy has no efficacy in slowing spinal radiographic progression in ankylosing spondylitis: results from 18-year longitudinal data MD Tae‐Han

**20. Spondyloarthritis – treatment 04/06/2020**

The Effect of Spinal Stabilization Exercises on Spinal Curves Diagnosed with Ankylosing Spondylitis Mr. Yasin

**20. Spondyloarthritis – treatment 04/06/2020**

Impact of body composition measures on the response to biological disease‐modifying anti‐rheumatic drugs in patients with ankylosing spondylitis MD Valeria

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

CAN FECAL CALPROTECTIN PREDICT FUTURE DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE IN AXIAL SPONDYLOARTHRITIS PATIENTS? – TREASURE REAL‐LIFE DATA MD Gözde Kübra

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Determination of patient‐physician discordance in global assessment in Spondyloarthritis MD Soraia

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Understanding Joint Replacement Surgery in Axial Spondyloarthropathy Dr. Sinead

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Clinical response to biologic DMARDs in axial spondyloarthritis and axial psoriatic arthritis. Different diseases, same outcomes? MD Diego

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Data to be collected for an optimal management of axial spondyloarthritis in daily practice: Proposal from an evidence based and consensual approaches Prof. Dr. Athan

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Onset of Axial Spondyloarthritis Repercussions on Patients’ Social and Family Life: Results from the European Map of Axial Spondyloarthritis (EMAS) Prof. Marco

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Diagnosis of axial spondyloarthritis in daily clinical practice – a survey among Dutch rheumatologists Dr. Anneke

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Anti‐CD74 IgA antibodies are most sensitive and specific to identify young male axial spondyloarthritis patients MD Ann‐Sophie

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Influence of smoking and obesity on therapeutic response in patients with axial spondyloarthritis: a systematic review and meta‐analysis Dr. Pablo

**21. Spondyloarthritis – clinical aspects (other than treatment) 04/06/2020**

Social isolation is independently associated with more severe disease in axial spondyloarthritis Dr. Sizheng Steven
33. Epidemiology, risk factors for disease or disease progression

- Specific acute reactions and inflammatory biomarkers in low doses of anuran toad offshore are associated with asthma and a population at risk for rheumatic arthritis. MD, PhD

- The use of new disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review. Dr.

- Serological confirmation of the development of new tuberculosis in patients with Ankylosing Spondylitis: results from a real-world data analysis. Dr.

- Overdose and risk factors for disease: a large cohort study in the Indian subcontinent. Epidemiologists and rheumatoid arthritis compared with first degree relatives and healthy controls evaluated in a single hospital from Colombia. MD

- The effect of correcting inflammation, oxidative stress and endothelial dysfunction in RVD patients with selected chronic diseases: A global observational study. Dr.

- Endothelial dysfunction in patients with autoimmune rheumatic diseases. Ms.

- The role of periostin and risk of patients in type 2 diabetes. Dr.

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Ga Young

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Michael L.

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Yoon D.

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Chao

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Rajan

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Min

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Mark

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Helen

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Helen

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Steve

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Steve

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Steve

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Phin

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. John

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. John

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Tom

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Tom

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Tom

- Epidemiology, risk factors for disease or disease progression 04/06/2020

- Dr. Tom
40. HPR Interventions (educational, physical, social and psychological)

The Effects of Pilates Training on Respiratory Muscle Strength in Patients with Ankylosing Spondylitis

M.S. Sengül

40. HPR Interventions (educational, physical, social and psychological)

Social support works better in Rheumatoid Arthritis than Fibromyalgia

Prof. Dr. Ayhan

40. HPR Interventions (educational, physical, social and psychological)

The Impact of Pilates Training on the Psychological Wellbeing of Patients with Fibromyalgia

Prof. Dr. Mehmet

40. HPR Interventions (educational, physical, social and psychological)

The Effects of Pilates on Respiratory Muscle Strength in Ankylosing Spondylitis Patients: Preliminary Results from an Open Clinical Trial

Dr. Şükrü

40. HPR Interventions (educational, physical, social and psychological)

The Role of Pilates in the Management of Ankylosing Spondylitis

Dr. Ayşe

40. HPR Interventions (educational, physical, social and psychological)

Cognitive Distress in Systemic Lupus Erythematosus with Juvenile-Onset: A Case Center Experience

M.S. Vina

40. HPR Interventions (educational, physical, social and psychological)

Psychological Particularities of Patients Suffering from Malignant Autoimmune Diseases

S. Suerba

40. HPR Interventions (educational, physical, social and psychological)

Influence of Support and Information on Self-management Support Needs Project of SKIN Rheumatology Research Group

Prof. Dr. Tarkan

40. HPR Interventions (educational, physical, social and psychological)

One-Year Follow-Up of a Multi-LED Team Intervention Effective in Reducing the Nocebo Effect When Switching from Originator Infliximab to a Biosimilar

MD. Isabelle

40. HPR Interventions (educational, physical, social and psychological)

Recommendations for Patients with Rheumatic Diseases in Treatment with Methotrexate

Mrs. Isabel

40. HPR Interventions (educational, physical, social and psychological)

Effect of thermoformable orthoses on foot function in rheumatoid arthritis patients: Preliminary results from an open clinical trial

Dr. Ilham

41. HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

Inactivity Behavior and Exercise Barriers in Patients with Behçet’s Disease

Mrs. Songul

41. HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

The Impact of Psoriatic Arthritis on Foot Health and Indication of Podiatry Need in a Secondary Care Setting

Prof. Dr. Yan

41. HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

AN AUDIT OF GLUCOCORTICOID PRESCRIPTION IN PATIENTS WITH GIANT CELL ARTERITIS

Dr. Hairul Hadi

41. HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

Implicated Factors in Therapeutic Adherence of Patients with Rheumatoid Arthritis: The Patient’s Perspective

Dr. María

41. HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

The Audit of Glucocorticoid Prescription in Patients with Giant Cell Arteritis

Ph D Laura

42. HPR Service developments, innovation and economics in healthcare

Can a Specialist Nurse Replace a Consultant - An Innovative Model for Osteoporosis Care

Ms. Julie

42. HPR Service developments, innovation and economics in healthcare

What Can We Learn From a Routine Frailty Assessment in Rheumatology? A Service Evaluation of 170 New Patient Referrals to a Single Rheumatology Centre.

Dr. Natasha

42. HPR Service developments, innovation and economics in healthcare

Barriers in Diagnosing Rheumatoid Arthritis - A Focus Group Study on the General Practitioners' Perspectives

Dr. Annette

43. HPR Professional education, training and competencies

Ultrasonic Education for Rheumatologist in Russia: Realities and What is Needed to Improve

Mrs. Natalia

43. HPR Professional education, training and competencies

Barriers for the Uptake of EULAR Postgraduate Education for Health Professionals in Rheumatology in Eastern European Countries: Results from 3 National Surveys

Prof. T.P.M.

43. HPR Professional education, training and competencies

Shared Decision Making amongst Rheumatologists in Training in the Netherlands: Where Do We Stand?

MD Laura

44. HPR Interdisciplinary research

Usefulness of Isotopic Radiosynoviorthesis in Rheumatic Diseases with Chronic Refractory Synovitis.

MD Joaquín

44. HPR Interdisciplinary research

Impact of Parental Migration in the Context of the Multifactorial Etiology of Chronic Arthritis in Childhood

Prof. Dr. Laura

44. HPR Interdisciplinary research

Effects of Vibroacoustic Therapy in Chronic Musculoskeletal Pain in Children and Adolescents

Prof. Dr. Constantin

48. Involvement and innovation in healthcare

An mHealth Tool for Shared Decision Making for Patients with Rheumatism and Arthritis

Prof. Dr. Yiannis

48. Involvement and innovation in healthcare

The Journey From Patient and Public Engagement (PPE) to Involvement: Facilitating Patient Partner Research Workshops with a Focus on Fibrofog in Fibromyalgia

Ms. Sandra

48. Involvement and innovation in healthcare

Peer Support of Patient and Public Involvement and Engagement in Research: The 'RUG-Buddy'

Mrs. Adele

48. Involvement and innovation in healthcare

Lead Patients – A Resource for Improvement of the Healthcare System

Ms. Madeleine